Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US EU | 2025

Login to access report north_east
Contact sales account_box

Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement. Agitation is commonly treated with off-label atypical antipsychotics, in spite of safety warnings they carry related to elevated risk of death in elderly dementia patients. In 2023, Lundbeck / Otsuka’s Rexulti (brexpiprazole) became the first FDA-approved drug to treat agitation associated with AD. Other novel agents are also emerging as potential treatments (e.g., Axsome’s Auvelity). Understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk / benefit profiles of today’s approved brand and off-label generic options will help identify opportunities for new product positioning and differentiation in this evolving market.

QUESTIONS ANSWERED

  • What are the most important treatment drivers and goals for prescribers in agitation in AD?
  • What attributes drive decision-making in agitation in AD, which have limited impact, and which are hidden opportunities?
  • How do Rexulti and off-label agents perform on these attributes?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes and price are neurologists willing to make for a hypothetical new drug to treat agitation in AD?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

  • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance
  • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers
  • Analyze market scenarios for different target product profiles using the TPP Simulator

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in February 2025

Key companies: Otsuka / Lundbeck

Key drugs: Rexulti, quetiapine, risperidone, olanzapine, aripiprazole, citalopram, gabapentin

Key feature

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east